Plasma Protein Therapeutics Market Size, Share, Trends, Growth 2032

Plasma Protein Therapeutics Market: Industry Prospective

The global plasma protein therapeutics market was approximately about USD24.94 billion in 2021 and is projected to rise to around USD 41.75 billion by 2028, with a compound annual growth rate (CAGR) of around 6.7% throughout the forecast period. The study examines the drivers, constraints, and challenges in the plasma protein therapeutics market, as well as their impact on demand throughout the forecast period. In addition, the research looks at the market for plasma protein therapeutics and new potential.

Request Free Sample

Plasma Protein Therapeutics Market: Overview

Plasma protein therapeutics is a type of biological therapy that uses plasma, a biological substance with a distinct biochemical profile that may be produced in a variety of ways. Plasma, which contains proteins, antibodies, salts, enzymes, and water, is the most abundant component in human blood. Platelets, white blood cells, and red blood cells are all excluded from plasma, which is the liquid component of blood. Plasma performs a variety of important transport tasks. Various chronic, life-threatening, uncommon, and hereditary disorders are treated with plasma protein therapeutics. They're utilized to treat immunological and autoimmune deficiencies, as well as bleeding and neurological diseases, as well as burns and shocks.

COVID-19 Impact:

The global market is projected to be significantly impacted by the COVID-19 pandemic. In the case of COVID-19, many biotech & pharmaceutical companies, research institutes, and government organizations in various countries are focusing on effective and rapid technologies for the rapid diagnosis of COVID-19, as well as creating vaccines and novel therapeutics to combat the situation. COVID-19 has a direct influence on production & demand, as well as market disruption and supply chain, with financial implications for businesses and financial markets. The outbreak of COVID-19 across the globe has in the short term ceased plasma donation, impacting the market for plasma protein therapeutics. Nevertheless, researchers are concentrating their efforts on plasma-based treatments to see if they might help cure the COVID-19 virus. This is likely to boost the market during the forecast period.

Request Free Sample

Plasma Protein Therapeutics Market: Growth Drivers

Growing incidences of chronic diseases to foster the market growth

The market is being primarily driven by the increasing incidence of over 200 life-threatening disorders that affect the neurological and immune systems, including idiopathic thrombocytopenic purpura, multifocal motor neuropathy, chronic inflammatory demyelinating polyneuropathy, and other infectious diseases such as varicella, tetanus, rabies, and hepatitis A & B. For instance, in the United States, the prevalence rate of idiopathic thrombocytopenic purpura (ITP) in individuals is around 66 incidences per 1,000,000 annually. Also, according to an epidemiological study on ITP in China, the annual incidence of ITP is 9.5 per 100,000, with adult females having a higher incidence than adult males (2:1), which might be connected to the fact that adult women are more prone to suffer autoimmune system illnesses. Further, the global plasma protein therapeutics market is boosted due to technological developments in reliable and cost-effective processes for separating proteins from plasma. Additionally, factors such as an increase in drug discovery & development programs, growing investment in R&D activities, and an increase in the number of clinical trials are propelling the market growth.

Report Scope:

Plasma Protein Therapeutics Market: Restraints

Strict regulations in different countries to impede the market growth

Plasma collection standards in developing nations do not meet the fractionator's requirements. These countries have stringent laws and regulations in place to ensure the quality of their operations, beginning with the quality of the raw materials. Plasma fractionators are built specifically for it. In Europe, for example, the plasma pool for fractionation must be screened for hepatitis A, B, & C, HIV, as well as Parvovirus B. Many facilities which collect the blood are unable to meet those requirements, resulting in some retrieved plasma being wasted. Additionally, each stage of the plasma protein therapy lifecycle is affected by the quality and regulatory norms, including donor compliance, quality, safety, pharmacovigilance, therapy safety & efficacy, and the biological license application process. All such factors may hinder the market growth.

Plasma Protein Therapeutics Market: Opportunities

High demand for Immunoglobulins (IG) to propel the market growth during the forecast period.

The number of medical indications for IG has been growing in recent years. Beyond primary immunodeficiency, IG has become a key therapy option for a variety of clinical reasons, including acute inflammatory and autoimmune diseases. Off-label prescription has also spread to nearly every medical profession. Demand for IG is rising as a result of off-label use in various applications, notably for the treatment of immunological deficiencies and neurological disorders. IG produced from plasma is used to treat a variety of inflammatory and autoimmune illnesses. Increased awareness and treatment of immunological weaknesses in developing countries have increased the global demand for immunoglobulin. Clinical demand for these drugs has risen in recent years, and this trend is projected to continue as diagnostic technology improves and life expectancy rises thereby generating ample opportunities for the global plasma protein therapeutics market growth during the forecast period.

Plasma Protein Therapeutics Market: Challenges.

Unfavorable reimbursement policies to pose major challenge to market growth

Budgets for health care are under increasing strain. Plasma protein treatments have been dragged into the terrain of Health Technology Assessments (HTA), including the prospective use of cost-utility analysis (CUA) in the allocation of reimbursement funds, owing to funding through reimbursement channels from commercial and public payers. Given the high cost of medicines and the young nature of many indications, the use of these health economics methods may limit the availability of medications for patients in true need. This may serve as a major challenge to the growth of the market.

Plasma Protein Therapeutics Market: Segmentation

The global plasma protein therapeutics market is categorized into product type, application, and region. Based on the product type, the global market is classified into coagulation factors, immunoglobulin, albumins, c1 esterase inhibitors, and others. The application segment is divided into idiopathic thrombocytopenic, secondary immunodeficiency, primary immunodeficiency disorder, hemophilia, hereditary angioedema, and others.

Recent Developments

• In April 2022, Biotest AG stated that the marketing authorization application for Biotest's expansion product IgG Next Generation under the decentralized procedure has been submitted in Austria and Germany by March 31, 2022. The preclinical and clinical research in the indications of chronic primary immune thrombocytopenia and primary immunodeficiency diseases (PID) are covered by the marketing authorization application, as well as the biochemical-pharmaceutical-technical portion (ITP).
• In April 2020, Takeda Pharmaceutical Company Limited and CSL Behring have formed a collaboration with Octapharma, LFB, BPL, and Biotest to discover a possible plasma-derived treatment for COVID-19.

Plasma Protein Therapeutics Market: Regional Landscape

North America to lead the market during the forecast period

North America is likely to lead the global plasma protein therapeutics market during the projected period. Factors such as the rising incidence and prevalence of neurological & autoimmune diseases are driving market expansion. The United States is likely to be the region's largest market. The region's growing geriatric population further expands the patient pool, as the aged people are more susceptible to neurological diseases. Furthermore, favorable government programs, rising blood donor awareness, the availability of improved protein fractioning processes, higher per capita income, and a spike in the proportion of research collaborations are all projected to boost market expansion in this region. On the other hand, Asia Pacific is estimated to grow at the fastest CAGR value owing to factors such as growing demand for advanced & effective options of treatment and developing healthcare infrastructure.

Plasma Protein Therapeutics Market: Competitive Landscape

The major players that are successfully operating in the global plasma protein therapeutics market are Biotest AG, CSL Behring, Grifols SA, Octapharma USA Inc., Takeda Pharmaceutical Company Ltd, Bio Products Laboratory, Shire PLC, Kedrion SpA, China Biologic Products Holdings Inc., and Baxter, among others.

Global plasma protein therapeutics market is segmented as follows:

By Product Type

• C1 esterase Inhibitors
• Albumins
• Immunoglobulins
• Coagulation Factors
• Others

By Application

• Hereditary Angioedema
• Hemophilia
• Primary Immunodeficiency Disorder
• Secondary Immunodeficiency
• Idiopathic Thrombocytopenic
• Others

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa